Cells that line the blood vessels do not behave identically but instead exhibit varied responses to the same...
Up To Date
Latest News
Staten Biotechnology has signed a dyslipidaemia licence option deal worth US$430m with Novo Nordisk.
Paris-based Kurma Partners announced the first closing of its Kurma Biofund III, a life science fund set to...
The European Parliament has voted to add €36.5bn to the budget of Horizon Europe (€94.1bn, in 2018 prices)...
Cancer immunotherapies are often associated with severe cytokine release syndrome (CRS) that can be managed...
Immuncheckpoint specialist Oxford BioTherapeutics has licenced the right to develop five bispecific antibodies...
Share
